Motor Neurone Diseases Pipeline Examined in Insightful Global Markets Direct Report Available at MarketPublishers.com

  Motor Neurone Diseases Pipeline Examined in Insightful Global Markets Direct
  Report Available at MarketPublishers.com

Business Wire

LONDON -- May 21, 2013

Motor neurone diseases (MND) results in a progressive paralysis which is
finally stopped by the patient’s death. They are rare - their annual incidence
is approximately 2.1 cases per 100,000 population. More common in people aged
over 50, the illnesses can be diagnosed at any age. Amyotrophic lateral
sclerosis (ALS) is the most common type of MDN.

Currently, the only drug used for the direct treatment of MND is Riluzole.
However, it does not help the patients to recover, but extend their survival
rates by around 3 months. Other medications used to treat MND include:
hyoscine, tizanidine, oral morphine, etc.

Market research report “Motor Neurone Diseases – Pipeline Review, H1 2013”
developed by Global Markets Direct offers a detailed review of worldwide
therapeutic scenario for motor neurone diseases. The study contains in-depth
overview of the diseases, data on products under development and top players
engaged in the therapeutic development for MND. The report provides
information on main discontinued pipeline projects, the most recent news and
activities relating to the field. Information on pipeline projects on the
basis of combined therapeutics and monotherapy is available in the study too.

Report Details:

Title: Motor Neurone Diseases – Pipeline Review, H1 2013

Published: April 30, 2013

Pages: 37

Price: US$ 2,000.00

http://marketpublishers.com/report/healthcare/therapy/motor-neurone-diseases-pipeline-review-h1-2013.html

Report Contents:

Introduction

Global Markets Direct Report Coverage

Motor Neurone Diseases Overview

Therapeutics Development

An Overview of Pipeline Products for Motor Neurone Diseases

Motor Neurone Diseases Therapeutics under Development by Companies

Motor Neurone Diseases Therapeutics under Investigation by
Universities/Institutes

Early Clinical Stage Products

Comparative Analysis

Discovery and Pre-Clinical Stage Products

Comparative Analysis

Motor Neurone Diseases Therapeutics – Products under Development by Companies

Motor Neurone Diseases Therapeutics – Products under Investigation by
Universities/Institutes

Companies Involved in Motor Neurone Diseases Therapeutics Development

Oxford BioMedica plc

NeuroSearch A/S

Omeros Corporation

Motor Neurone Diseases – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

MoNuDin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NRP-2945 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GPR139 Antagonist - Drug Profile

Product Description

Mechanism of Action

R&D Progress

…

More market research reports by Global Markets Direct can be found at
http://marketpublishers.com/members/globalmarketsdir/info.html

Contact:

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com
 
Press spacebar to pause and continue. Press esc to stop.